Histologic Tumor Necrosis Is an Independent Prognostic Indicator for Clear Cell and Papillary Renal Cell Carcinoma

被引：71

作者：

Pichler, Martin ^{[2
]}

Hutterer, Georg C. ^{[1
]}

Chromecki, Thomas F. ^{[1
]}

Jesche, Johanna ^{[1
]}

Kampel-Kettner, Karin ^{[1
]}

Rehak, Peter ^{[3
]}

Pummer, Karl ^{[1
]}

Zigeuner, Richard ^{[1
]}

机构：

[1] MUG, Dept Urol, A-8036 Graz, Austria

[2] MUG, Dept Internal Med, Div Oncol, A-8036 Graz, Austria

[3] MUG, Res Unit Biomed Engn & Comp, A-8036 Graz, Austria

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2012年 / 137卷 / 02期

关键词：

Prognosis; Renal cell carcinoma; Tumor necrosis; Papillary type; RADICAL NEPHRECTOMY; SURVIVAL; FEATURES; CANCER; CLASSIFICATION; PROGRESSION; PREDICTION; UTILITY; STAGE;

D O I：

10.1309/AJCPLBK9L9KDYQZP

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Histologic tumor necrosis (TN) has been reported to indicate a poor prognosis for different human cancers. In papillary renal cell carcinoma (RCC), data regarding the prognostic impact of TN are conflicting. We retrospectively studied the pathology records of 2,333 consecutive patients who underwent nephrectomy from 1984 to 2006 at a single tertiary academic center. In multivariate analyses regarding clear cell RCC, the presence of histologic TN was an independent negative prognostic factor for metastasis-free (hazard ratio [HR], 2.32; confidence interval [CI], 1.86-2.9; P < .001) and overall (HR, 1.52; CI, 1.31-1.76; P < .001) survival. Regarding papillary RCC, the presence of histologic TN represented an independent predictor of metastasis-free (HR, 5.22; CI, 2.2-12.5; P < .001) and overall (HR, 1.69; CI 1.11-2.58; P = .015) survival. Our findings suggest that the presence of TN is an independent predictor of clinical outcome in clear cell and papillary RCC. Thus, histologic TN might be a reliable prognostic indicator and should, therefore, routinely be examined during pathologic analysis of RCC specimens.

引用

页码：283 / 289

页数：7

共 37 条

[1] Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials [J].